Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors

NCT05537740 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05537740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 11, 2022
Completion date
May 4, 2027
Enrollment
129 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors